Consolidated Financial Results for the Second Quarter of Fiscal Year Ending March 31, 2027 (IFRS)10/29 12:00TDnetPDF(665KB)
2nd Quarter of Fiscal Year 2026 (Ending March 31, 2027) (April 1, 2026 to September 30, 2026) Supplementary Materials (Consolidated IFRS)10/29 12:00TDnetPDF(662KB)
Ono Pharma Announces an Exclusive License Agreement with Biohaven to Develop and Commercialize IgG Degraders in Japan, South Korea, Taiwan, and ASEAN 10/8 17:00TDnetPDF(233KB)
Consolidated Financial Results for the First Quarter of Fiscal Year Ending March 31, 2027 (IFRS)7/31 12:00TDnetPDF(373KB)
Notice concerning Completion of Disposal of Treasury Shares as Tenure-based Restricted Stock Compensation and Performance-linked Restricted Stock Comp7/10 12:00TDnetPDF(139KB)
Notice of Disposal of Treasury Shares as Tenure-based Restricted Stock Compensation and Performance-linked Restricted Stock Compensation6/18 16:30TDnetPDF(160KB)
Fiscal Year 2025 (April 1, 2025 to March 31, 2026) Supplementary Materials (Consolidated IFRS)5/8 12:00TDnetPDF(750KB)
Consolidated Financial Results for the Fiscal Year Ended March 31, 2026 (IFRS)5/8 12:00TDnetPDF(504KB)
(Correction) Partial Correction to the ‘‘Notice concerning Disposal of Treasury Shares by Third-Party Allotment’’3/5 16:40TDnetPDF(137KB)
Notice concerning Introduction of Long-Term Incentive Stock Plan for Employees of Deciphera, the U.S. Subsidiary3/5 12:00TDnetPDF(151KB)
Announcement concerning the Transfer of Distribution Sales and Termination of Co-promotion for SGLT2 Inhibitor Forxiga 5 mg 10 mg in Japan2/27 16:00TDnetPDF(210KB)